Shirley Lewis

Dr. Shirley Lewis


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Indian Journal of Palliative Care
Verified
Journal Article
Open access
PDF file
SSSaurabh Samdariya
Saurabh Samdariya
SLShirley Lewis
Shirley Lewis
HKHeena Kauser
Heena Kauser
IAIqbal Ahmed
Iqbal Ahmed
DKDewesh Kumar
Dewesh Kumar
Background: There are various drugs tried for relieving pain associated with radiation-induced mucositis. This paper aims to study role of honey in relieving pain due to radiation induced mucositis in head and neck cancer patients receiving concomitant chemoradiation. Materials and Methods: A randomized controlled trial on 78 subjects (40 in test group and 38 in control group) was undertaken to study the analgesic effect of honey, but the analysis of 69 patients was done as nine patients (four in test and five in control group) were lost to follow-up or left treatment in between the study. All patients were advised to do salt-soda and benzydamine mouth gargles, alternatively every 3 hours. Test group patients additionally received 20 ml honey three times a day during the entire course of radiation treatment and 3 months following radiation therapy (RT). Results: Honey significantly reduced the severity of mucositis associated pain and resulted in lesser treatment gaps and a decrease in overall radiotherapy treatment duration. None of the test group and majority of controls (51.5%) had severe pain score during the 7th week of RT. The same pattern was seen in the post-RT period. Mean pain score was significantly different in both groups during all weeks during and upto 6 weeks post-RT (mean score of 3.08 and 6.54 for test and control respectively at 7th week RT, P < 0.001). Conclusion: Honey being a cheap, palatable, and natural medicament can be used for decreasing pain associated with radiation-induced mucositis in cancer patients.

1 January 2014 in Journal of Cancer Research and Therapeutics
Verified
Journal Article
Closed access
NSNaveen Salins
Naveen Salins
SLShirley Lewis
Shirley Lewis
MRMraghavendra Rao
Mraghavendra Rao
AKAmrit Kadam
Amrit Kadam
Nts on active cancer treatment were enrolled to the study. Functional assessment of chronic illness therapy-spirituality (FACIT-Sp) and FACIT-Fatigue scales were used to assess spiritual well-being and fatigue scores during their cancer treatment. Data were analyzed using one-way analysis of variance and bivariate relationships determined using the Spearman Correlation analysis. Linear regression analysis was performed to determine predictors of fatigue score during treatment. Results: Mean spiritual well-being score was 20.96 out of 48 and scores were significantly higher in females compared with males (P = 0.03), lower with higher stage (P = 0.008) and lower in head and neck and gastrointestinal malignancies (P = 0.03) when compared with gynecological and breast malignancies. Fatigue was present in all the 200 patients studied and the mean fatigue score was 13.09. Higher fatigue scores were observed in patients with advanced stages of cancer (Stage IV) (F [3,199] = 5.67, P = 0.001). There was a significant inverse relationship between fatigue scores with spiritual well-being (P < 0.001). Spiritual well-being score emerged as a significant primary negative predictor (β = -0.23, P = 0.001) for fatigue scores followed by stage of disease (β =0.23, P = 0.001) and gender (β = -0.18, P = 0.01) as significant secondary predictors. Conclusion: Fatigue during cancer directed treatment is influenced by spiritual wellbeing, disease stage and gender. Further studies should examine the mediating variables that influence fatigue....

24 February 2022 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
Jill KolesarJill Kolesar
Jill Kolesar
SPSpencer Peh
Spencer Peh
LTLevin Thomas
Levin Thomas
GBGayathri Baburaj
Gayathri Baburaj
NMNayonika Mukherjee
Nayonika Mukherjee
MRMahadev Rao
Mahadev Rao
The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently, further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450 enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs.

1 January 2013 in Indian Journal of Palliative Care
Verified
Journal Article
Open access
NSNaveen Salins
Naveen Salins
AKAmrit Kadam
Amrit Kadam
RRRaghavendra Rao
Raghavendra Rao
SLShirley Lewis
Shirley Lewis
Distress is commonly seen in head and neck cancer patients undergoing radiotherapy. Causal factors of distress are multifactorial; which encompasses physical, psychological, spiritual, and existential factors with complex interrelationship among the factors. Thirty patients undergoing head and neck radiotherapy were included in the study. Patients were screened for pain scores, distress scores, physical and psychological symptoms, and spiritual and emotional distress. Significant increasing trend seen for pain score, distress score, and total number of symptoms during 2(nd) week, 4(th) week, and on completion of radiotherapy treatment (all P's < 0.001) compared to pretreatment. Those who had chemotherapy (CT) along with radiation had significantly greater pain score (t = 5.54, P = 0.03) and distress score (t = 3.9, P = 0.05) at 2 weeks into radiotherapy compared to those who did not receive CT. There was significantly higher grade of skin toxicity in those with spiritual distress (Somers' d = 0.36, P = 0.02) and higher grade of mucositis in those with existential distress (d = 0.34, P = 0.02) at 4 weeks into radiotherapy. Positive correlation between distress score and pain score and occurrence of physical symptoms. Increasing trend seen for pain score, distress score, and total number of symptoms during 2(nd) week, 4(th) week, and completion of radiotherapy treatment compared to pretreatment. Increase in distress score in those with existential and spiritual distress.

1 September 2017 in Brachytherapy
Verified
Journal Article
Closed access
SCSantam Chakraborty
Santam Chakraborty
UMUmesh Mahantshetty
Umesh Mahantshetty
SCSupriya Chopra
Supriya Chopra
SLShirley Lewis
Shirley Lewis
VHVinod Hande
Vinod Hande
SSShyam Kishore Shrivastava
Shyam Kishore Shrivastava

1 October 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
VMVedang Murthy
Vedang Murthy
SLShirley Lewis
Shirley Lewis
SKSadhana Kannan
Sadhana Kannan
CKChira Ranjan Khadanga
Chira Ranjan Khadanga
VRVenkatesh Rangarajan
Venkatesh Rangarajan
JAJai Prakash Agarwal
Jai Prakash Agarwal